DALLAS, April 09, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a treatment for epilepsy derived from the company’s patented cannabis extraction method is under research and development. “Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals,” said Kali-Extracts, CEO Frederick Ferri. The company currently has ongoing cannabis extract research and development targeting four specific health issues, Chronic Obstructive Pulmonary Disease (COPD), Type 2 Diabetes, Cancer Pain Management and Epilepsy. KALY plans to publish an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024. The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.
In addition to its pharmaceutical developments, KALY is generating revenue from its patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. KALY announced last week finalizing it’s all new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC: PURA) (“PURA”) leading EVERx CBD Sports Water. KALY has also recently announced plans to provide commercial extraction for Nouveau, Inc. (USOTC: NOUV) (“NOUV”) in conjunction with NOUV’s recently announced 100-acre hemp farm.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.